Transduction of hematopoietic stem cells to stimulate RNA interference against feline infectious peritonitis

Eman A Anis1,2, Madhu Dhar3, Alfred M Legendre4

  • 11 Infectious Diseases, Veterinary Diagnostic and Investigational Laboratory, College of Veterinary Medicine, University of Georgia, Tifton, GA, USA.

Insights

This study developed lentivirus vectors expressing micro (mi)RNA to combat feline coronavirus (FCoV). Genetically modified hematopoietic stem cells (HSCs) effectively reduced FCoV replication in vitro, showing promise for feline infectious peritonitis (FIP) treatment.

Area of Science:

  • Veterinary Virology
  • Gene Therapy
  • Molecular Biology

Background:

  • Feline infectious peritonitis (FIP) is a severe disease caused by feline coronavirus (FCoV).
  • Current treatments for FIP are limited, necessitating novel therapeutic strategies.
  • Antiviral therapies targeting viral replication are under investigation.

Purpose of the Study:

  • To develop lentivirus vectors encoding anti-FCoV micro (mi)RNA for potential FIP therapy.
  • To assess the feasibility of transducing feline hematopoietic stem cells (HSCs) with these vectors.
  • To evaluate the efficacy of miRNA-mediated inhibition of FCoV replication in HSCs.

Main Methods:

  • Construction of lentivirus vectors expressing anti-FCoV miRNAs.
  • Ex vivo transduction of feline HSCs with selected lentivirus vectors.
  • In vitro infection of transduced HSCs with FCoV strains.
  • Quantification of viral genomic RNA and extracellular virus production.

Main Results:

  • One miRNA (miRNA-L2) targeting the viral leader sequence showed significant FCoV inhibition.
  • Stably transduced HSCs expressing miRNA-L2 demonstrated substantial reductions in FIPV and FECV replication.
  • Reductions in viral genomic RNA synthesis ranged from 74% to 92%.

Conclusions:

  • Genetic modification of HSCs to constitutively produce anti-coronavirus miRNA is a viable strategy.
  • This approach effectively reduces FCoV replication in vitro.
  • These findings support the potential of miRNA-based gene therapy for FIP.